Nuvaira Stock

nuvaira.comHealthcare / Other HealthcareFounded: 2008Funding to Date: $150.32MM

Nuvaira is a medical device company that develops therapies to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology.

Register for Details

For more details on financing and valuation for Nuvaira, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Nuvaira.

Register Today

Team

Management Team

Dennis Wahr MD
President, Chief Executive Officer and Board Member
Lorraine Marshall Wright
Senior Marketing Consultant
Jim Pavliska
Vice President of Clinical Affairs
Kari Golembeck Kubesh
Chief Financial Officer
Joseph Ostendorg
Regulatory Affairs & Quality Systems Manager
Martin Mayse MD
Chief Technology Officer & Co-Founder
Shane Gleason
Chief Commercial Officer
Mahtab Fatemi JD
Vice President, Regulatory Affairs & Quality

Board Members

Christopher Shen MD
Qiming Venture Partners
Jonathan Root MD
US Venture Partners
Kirk Nielsen
Versant Venture Management
Carolyn Ng Ph.D
Vertex Ventures HC
Henry Plain Jr.
Morgenthaler Ventures
Mark Deem
Lightstone Ventures
David Stassen
Split Rock Partners
James Lee Tze Wei
Alexander Schmitz
Endeavour Vision
Michael Carusi
Advanced Technology Ventures

Other companies like Nuvaira in the Other Healthcare sector

Sector
Last Round Est. Valuation
$165MM
Sector
Last Round Est. Valuation
$368.08MM
Sector
Last Round Est. Valuation
$150MM
Sector
Last Round Est. Valuation
$125MM
Sector
Last Round Est. Valuation
$140MM
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$173.59MM
Sector
Last Round Est. Valuation
$300.91MM

News Highlights

Minneapolis-Based Nuvaira Raises $79 Million To Fight Chronic Lung Diseases
Minneapolis, Minnesota-based Nuvaira has raised $79 million in funding to further develop its novel therapeutic medical devices for treating obstructive lung diseases.
Updated on: Oct 3, 2023

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.